Our reporter Zhang Min
On November 10th, Baekje Shenzhou announced its US stock market performance report and A-share performance report for the third quarter of 2023.
Baiji Shenzhou achieved a total operating revenue of 5.624 billion yuan in the third quarter, a year-on-year increase of 111.5%. Thanks to strong demand for core products, product revenue maintained a high growth rate this quarter, reaching 4.287 billion yuan, a year-on-year increase of 79.2%.
In the first three quarters of 2023, the total operating revenue of Baekje Shenzhou was 12.875 billion yuan, an increase of 87.4% year-on-year. In the first three quarters, the product revenue of Baekje Shenzhou exceeded the 10 billion mark for the first time, reaching 10.984 billion yuan, a year-on-year increase of 81%, significantly exceeding the full year product revenue of last year.
As the first innovative drug approved by Baekje Shenzhou in the international market, Baekje&Co; Reg; In the third quarter, global sales reached 2.571 billion yuan, with US stock market financial reports showing a year-on-year increase of 130%. Among them, the sales revenue in the United States reached 1.937 billion yuan, an increase of more than double compared to 740 million yuan in the same period last year. In China, Zebutinib's sales reached 344 million yuan, compared to 270 million yuan in the same period last year. Since the beginning of this year, Zebutinib's global sales have achieved continuous month on month growth, with overseas revenue accounting for over 80% in the third quarter.
In terms of research and development, Baekje Shenzhou has a rich global research and development pipeline reserve, with a total of 23 development projects and over 60 preclinical projects under research.
In terms of production, the financial report shows that the company's total production capacity at the Guangzhou biopharmaceutical production base has reached 64000 liters. In addition, the new small molecule innovative drug industrialization base in Suzhou will be completed this month. In New Jersey, the new production base and clinical research and development center are entering the final construction phase and are expected to be operational in the summer of 2024.